# S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

> **NCT00006708** · PHASE3 · TERMINATED · sponsor: **SWOG Cancer Research Network** · enrollment: 7 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** rituximab
- **DRUG:** carboplatin
- **DRUG:** etoposide
- **DRUG:** ifosfamide

## Key facts

- **NCT ID:** NCT00006708
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-10
- **Primary completion:** 2002-11
- **Final completion:** 2006-11
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** lack of accrual
- **Last updated:** 2013-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006708, "S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00006708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*